~~<i id='161E95960B'><strike id='161E95960B'><tt id='161E95960B'><pre id='161E95960B'></pre></tt></strike></i>~~

Home» knowledge» knowledge

knowledge

author：focus 2025-09-28 10:18:03 Page View：81293

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Baby aspirin cuts fat buildup in liver disease patients, in small study
Next article： Apple is now the first public company to be valued at $3 trillion

leisure time

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

US recommends Americans reconsider traveling to China due to arbitrary law enforcement, exit bans

BEIJING--TheU.S.recommendedAmericansreconsidertravelingtoChinabecauseofarbitrarylawenforcementandexi

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

PlayStation controller and acoustic messaging: How the missing Titanic tourist sub works

1:15FileimageoftheTitansubmersiblepriortocommencediving.OceanGateThesubmersiblethatwasreportedmissin

WSS

knowledge

knowledge

explore

leisure time

PlayStation controller and acoustic messaging: How the missing Titanic tourist sub works